Skip to main content

Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Site Search
Reata Pharmaceuticals Inc. logo
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window

HSP90 Modulators

  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations

Cemdomespib
Click here to enlarge

Cemdomespib

Cemdomespib is the lead product candidate from our Hsp90 modulator program. Cemdomespib is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90.

Historically, other companies have explored N-terminal Hsp90 inhibitors for cancer therapeutics; however, this approach has been associated with multiple adverse effects including peripheral neuropathy and ocular toxicity. Binding at the C-terminus of Hsp90 leads to increased transcription of Hsp70, a cytoprotective and molecular chaperone gene, which facilitates cell survival in response to stress without the deleterious activities of N-terminal inhibition.

We have observed favorable activity of Cemdomespib in a range of preclinical models of neurological disease, including models of diabetic neuropathy, neuroinflammation, and neuropathic pain. In preclinical rodent disease models, we observed that Cemdomespib administered orally once-daily rescued existing nerve function, restored thermal and mechanical sensitivity within four weeks, and improved nerve conductance velocity and mitochondrial function. These effects are dose-dependent, reversible, and HSP70-dependent.

Follow the links to:

  • Learn more about our developmental program in diabetic peripheral neuropathic pain (DPNP).
  • Learn about Cemdomespib in our pipeline.
Blue Bonnets
Reata Pharmaceuticals Inc. logo

Intended for US residents only.

  • Sitemap
  • Legal Message
  • Privacy Notice
  • Social Media Disclosure
  • Contact Us
Powered By Q4 Inc. 5.104.0.1 (opens in new window)

© Reata Pharmaceuticals, Inc., All Rights Reserved. | US-NON-2100018 | 09/2023

Stay Connected Mobile

  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window